What is Vergent Bioscience?
Vergent Bioscience is dedicated to revolutionizing cancer surgery through its lead compound, VGT-309. This fluorescent imaging agent is designed to precisely identify and visualize previously undetected tumors in real-time during surgical procedures. By enabling surgeons to ensure the complete removal of solid tumor tissue, Vergent aims to enhance the efficacy and accessibility of minimally invasive and robotic-assisted cancer surgeries. The company's mission is to transform patient outcomes for those battling solid tumors by optimizing surgical precision and completeness.
How much funding has Vergent Bioscience raised?
Vergent Bioscience has raised a total of $48.9M across 3 funding rounds:
Series A
$8.7M
Series B
$21.5M
Private Equity
$18.7M
Series A (2018): $8.7M, investors not publicly disclosed
Series B (2022): $21.5M led by Colle Capital, Rex Health Ventures, Orlando Health Ventures, Spring Mountain Capital, Windham Venture Partners, and Intuitive Surgical
Private Equity (2025): $18.7M, investors not publicly disclosed
Key Investors in Vergent Bioscience
Colle Capital
Colle Capital Partners is a global early-stage technology venture fund that focuses on investing in innovative entrepreneurs and their bold ideas. The fund emphasizes the importance of data for measuring and managing investments while encouraging agility in a competitive environment.
Rex Health Ventures
Rex Health Ventures (RHV) is an innovative platform established by UNC REX Healthcare to support and invest in healthcare technologies and companies. As an early-stage investment fund, it aims to enhance patient care by providing strategic investments to emerging healthcare entrepreneurs.
Intuitive Surgical
Intuitive Surgical Operations, Inc. is a pioneering medical technology company that develops, manufactures, and markets robotic-assisted surgical systems and related instruments and accessories designed to enhance the capabilities of surgeons and improve patient outcomes.
What's next for Vergent Bioscience?
With the recent influx of major strategic investment and substantial overall capital, Vergent Bioscience is poised for significant growth and expansion. The company is likely to focus on advancing its clinical trials, scaling manufacturing capabilities for VGT-309, and forging strategic partnerships to broaden market penetration. This substantial backing from enterprise-level investors signals strong confidence in Vergent's technology and its potential to significantly improve cancer care, paving the way for enhanced surgical outcomes and a more accessible approach to cancer treatment.
See full Vergent Bioscience company page
